...

首页> 外文期刊>Leukemia and lymphoma >Characterization and significance of the Philadelphia negative/BCR-ABL1 positive rearrangement or masked Philadelphia translocation in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single-center study

【24h】

Characterization and significance of the Philadelphia negative/BCR-ABL1 positive rearrangement or masked Philadelphia translocation in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single-center study

机译：酪氨酸激酶抑制剂治疗慢性骨髓白血病患者的费城阴性/ BCR-ABL1阳性重排或蒙皮畸形的表征及意义：单中心研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Leukemia and lymphoma》 |2020年第2期|共5页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Characterization and significance of the Philadelphia negative/BCR-ABL1 positive rearrangement or masked Philadelphia translocation in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single-center study [J] . Leukemia and lymphoma . 2020,第1a2期

机译：酪氨酸激酶抑制剂治疗慢性骨髓白血病患者的费城阴性/ BCR-ABL1阳性重排或蒙皮畸形的表征及意义：单中心研究
2. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: Final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study [J] . BaccaraniM., DrukerB.J., BranfordS., International journal of hematology . 2014,第5期

机译：慢性期费城染色体阳性慢性粒细胞白血病患者的初始剂量不受伊马替尼的长期反应：酪氨酸激酶抑制剂优化和选择性（TOPS）研究的最终更新
3. Factors influencing a second myeloid malignancy in patients with Philadelphia-negative -7 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemia [J] . Michael J. Groves, Mark Sales, Lee Baker, Cancer genetics . 2012,第1a2期

机译：费城阴性-7或del（7q）克隆患者酪氨酸激酶抑制剂治疗慢性粒细胞白血病期间影响第二次髓样恶性肿瘤的因素
4. Novel Inhibitors of T315I Mutant BCR-ABL1 Tyrosine Kinase for Chronic Myeloid Leukemia Disease Through Fragment-Based Drug Design [C] . Satya Anindita, Atika Marnolia, Hersal Hermana Putra, International symposium on bioinformatics research and applications . 2018

机译：T315I突变BCR-ABL1酪氨酸激酶的新型抑制剂通过基于片段的药物设计治疗慢性粒细胞白血病
5. Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor [O] . Gyan K Kayastha, Padma Gurung, Paras K Acharya, 2010

机译：帕坦医院治疗格列卫（甲磺酸伊马替尼）治疗费城染色体/ BCR-ABL1阳性慢性髓性白血病患者的经验；第一代特异性酪氨酸激酶抑制剂
6. Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor [O] . Zimmerman Mark, Hayes Bruce, Paudyal Buddhi P, 2010

机译：帕坦医院治疗格列卫（甲磺酸伊马替尼）治疗费城染色体/ BCR-ABL1阳性慢性髓性白血病患者的经验；第一代特异性酪氨酸激酶抑制剂

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号